Alpha Tau to Participate in September Investor Conferences
Alpha Tau Medical (DRTS) announced that CFO Raphi Levy will participate in two investor conferences in September 2026 in New York.
Rhea-AI Summary
Alpha Tau Medical (DRTS) announced that CFO Raphi Levy will participate in two investor conferences in September 2026 in New York.
He will hold 1x1 meetings at Citi's 2026 Biopharma Back to School Conference on Wednesday, September 9, 2026. He will also take part in a fireside chat and 1x1 meetings at the H.C. Wainwright 28th Annual Global Investor Conference on Monday, September 14, 2026, from 9:30–10:00AM ET. Interested investors are asked to contact Citi or H.C. Wainwright representatives to schedule meetings.
Positive
- None.
Negative
- None.
Market Reaction – DRTS
Following this news, DRTS has gained 2.38%, reflecting a moderate positive market reaction. Our momentum scanner has triggered 4 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $14.29.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 31 | Patient enrollment | Positive | -3.6% | Completed enrollment after expanding the pancreatic cancer pilot study to 48 patients |
| Aug 17 | Board appointment | Neutral | -0.7% | Appointed a director to chair Nano Dimension's strategy and capital allocation committee |
| Aug 10 | 2Q26 earnings | Positive | +4.9% | Reported collaboration, clinical progress, higher cash and a six-month net loss |
| Aug 10 | Dual listing | Neutral | +3.5% | Registered 92,478,154 outstanding shares for a planned Tel Aviv Stock Exchange listing |
| Jul 21 | Clinical data | Positive | -1.1% | Reported a 100% objective response rate and 18.2-month median overall survival |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Historical reactions were mixed, with DRTS diverging from positive enrollment and clinical-data announcements but aligning with positive earnings and listing news.
AI-generated analysis. How Rhea-AI works. Not financial advice.
JERUSALEM, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (“Alpha Tau”, or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CFO Raphi Levy will participate in the following investor conferences in September 2026.
| Event: | Citi's 2026 Biopharma Back to School Conference |
| Format: | 1x1 Meetings |
| Date: | Wednesday, September 9, 2026 |
| Location: | New York, NY |
| Event: | H.C. Wainwright 28th Annual Global Investor Conference |
| Format: | Fireside Chat and 1x1 Meetings |
| Date: | Monday, September 14, 2026 |
| Time: | 9:30 – 10:00AM ET |
| Location: | New York, NY |
Mr. Levy will be available for 1x1 investor meetings at all conferences. Please reach out to your Citi or H.C. Wainwright representatives to schedule.
About Alpha Tau Medical Ltd.
Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.
About Alpha DaRT®
Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it.
Investor Relations Contact:
